Want to see JP:4592 full AI Analyst Report?
4592 Stock Chart & Stats
¥957.00
¥9.00(0.94%)
At close: 4:00 PM EDT
¥957.00
¥9.00(0.94%)
Day’s Range― - ―
52-Week Range¥874.00 - ¥3,990.00
Previous CloseN/A
Volume557.50K
Average Volume (3M)2.08M
Market Cap
¥79.39B
Enterprise Value¥133.51K
Total Cash (Recent Filing)¥14.00B
Total Debt (Recent Filing)¥1.18B
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Sep 14, 2026EPS Estimate
-4.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.94
Shares Outstanding78,058,880
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,475.00Price Target Upside54.13% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-57.95
Revenue Forecast (FY)¥373.28M
Bulls Say, Bears Say
Bulls Say
Proprietary Allogeneic Cell Therapy PlatformSanBio’s ownership of an allogeneic (donor-derived) cell therapy platform, anchored by SB623, is a durable strategic asset. A platform approach can support multiple indications, enables licensing or partnerships, and offers longer-term optionality versus a single product program if clinical proof is achieved.
Improved Equity Position And Generally Manageable LeverageA materially larger equity base and historically modest debt-to-equity in recent years improve solvency and provide a clearer runway against near-term funding shocks. This stronger balance-sheet position reduces immediate bankruptcy risk and supports continued clinical development and regulatory activities.
In-house R&D, Manufacturing And Regulatory CapabilitiesOwning end-to-end capabilities — R&D, manufacturing/process development, and regulatory/commercial prep — is a durable competitive advantage in cell therapy. It lowers reliance on external partners for critical tech transfer, can speed commercialization and helps preserve IP/control over product quality and costs long-term.
Bears Say
Zero Commercial RevenueSanBio remains pre-commercial with no recurring product sales, meaning durable funding and value creation rely entirely on successful clinical outcomes or partner deals. Without commercial revenue, the company faces sustained execution risk and its long-term viability depends on achieving approvals or licensing events.
Sustained Heavy Operating Cash BurnConsistent multi-year negative operating and free cash flow indicates the company requires recurring external financing to fund development. This structural cash-burn dynamic elevates dilution and refinancing risk, potentially constraining R&D pace or commercialization investment over the medium term.
Persistent Large Net Losses And Negative Returns On EquityMaterial and persistent net losses have produced deeply negative ROE, eroding investor capital over time. Until the business generates positive operating margins or recurring sales, negative profitability will pressure the balance sheet and make sustained independent growth difficult without dilutive funding or transformative partnerships.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥874.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥79.39B.
When is SanBio Co Ltd’s upcoming earnings report date?
SanBio Co Ltd’s upcoming earnings report date is Sep 14, 2026 which is in 30 days.
How were SanBio Co Ltd’s earnings last quarter?
SanBio Co Ltd released its earnings results on Jun 15, 2026. The company reported -¥10.71 earnings per share for the quarter, missing the consensus estimate of -¥6.194 by -¥4.516.
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Undervalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate is -4.8.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,058,880 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
SanBio Co Ltd reported an EPS of -¥10.71 in its last earnings report, missing expectations of -¥6.194. Following the earnings report the stock price went up 0.749%.
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q4 2026
0:00 / 0:00
4592 Stock 12 Month Forecast
Average Price Target
¥1,475.00
▲(54.13% Upside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―